{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"69","upperLimit":"351","value":"213"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Median time to relapse after achieving complete remission (CR). CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:\n\n1. Normal bone marrow with blasts \\<5% with normal cellularity, normal megakaryopoiesis, \\> 15% erythropoiesis and \\> 25% granulocytopoiesis\n2. Normalization of blood counts (no blasts, platelets \\> 100000/mm3, granulocytes \\>1500/mm3)\n3. No extramedullary disease.\n\nRelapse Criteria:\n\n1. After CR: \\>5% blasts in the bone marrow and/or peripheral blood\n2. After partial remission (PR): increase of blasts cells in the marrow to \\>50% of those during PR\n3. Extramedullary disease confirmed cytologically or histologically.","dispersionType":"Full Range","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive 90Y-BC8 via central line on approximately day -12, fludarabine phosphate IV over 30 minutes on days -4 to -2, and 2 Gy TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSC or bone marrow transplant on day 0.\n\nGVHD PROPHYLAXIS: Patients receive mycophenolate mofetil PO or IV every 12 hours on days 0-27 (for patients with related donors) or every 8 hours on days 0-40 with taper to day 96 (for patients with unrelated donors). Patients also receive cyclosporine PO or IV every 12 hours on days -3 to 56 (for patients with related donors) or 100 (for patients with unrelated donors) with taper to day 180.\n\nAllogeneic Bone Marrow Transplantation: Undergo allogeneic bone marrow transplant\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo allogeneic PBSC or bone marrow transplant\n\nCyclosporine: Given PO or IV\n\nFludarabine Phosphate: Given IV\n\nIndium In 111 Anti-CD45 Monoclonal Antibody BC8: Given IV (dosimetric dose)","id":"OG000","title":"Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)"}],"paramType":"MEDIAN","populationDescription":"Study participants who relapsed after achieving complete remission after transplant.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Duration of Remission","type":"SECONDARY","unitOfMeasure":"days"}